Key Highlights

  • Sonic runs pathology laboratories across several countries, so its Revenue is built on the huge Volume of everyday medical tests.
  • FY2026 revenue rose 13% to A$10,867 million and net profit rose 17% to A$621 million, aided by acquisitions.
  • Steady 5% organic growth reflects the reliable, recurring Demand for diagnostic testing.
  • Sonic Healthcare (ASX:SHL) is one of the world's largest medical-diagnostics companies and a member of the S&P/ASX 200 health care.

Sonic Healthcare (ASX:SHL) is one of the world's largest medical-diagnostics companies and a member of the S&P/ASX 200 health care sector. Its core Business is pathology — the laboratory testing of blood, tissue and other samples that doctors order to diagnose and monitor illness. Every day, across Australia, Germany, the United States, Switzerland and other countries, Sonic's laboratories process an enormous volume of these tests. How everyday diagnostic tests support the business is the foundation of the company: this steady, high-volume, recurring demand generates reliable revenue and, through scale, healthy profits.

The FY2026 result, for the year ended 30 June 2026, showed solid organic growth supplemented by acquisitions, delivering double-digit revenue and profit growth.

A solid result

Sonic reported total revenue of A$10,867 million, up 13%, with underlying EBITDA of A$1,933 million, up 11%, and net profit after tax of A$621 million, up 17%. Earnings Per Share rose 14% to 125.6 cents. The result was within the company's guidance range, and the board declared total dividends of A$1.08 a share.

Underpinning the result was organic revenue growth of 5% across the group, supported by demographic trends and Sonic's market positions, with acquisitions adding further growth, particularly in Germany. The combination of steady organic growth and acquisitions is Sonic's long-standing formula.

Why testing volume is the foundation

Diagnostic testing is one of the most fundamental and high-volume activities in healthcare. Doctors rely on pathology to diagnose conditions, guide treatment and monitor patients, so a vast number of tests are ordered every day — blood tests, biopsies, screening and much more. This demand is largely non-discretionary and recurring: people need testing when they are unwell, undergoing treatment or being screened, regardless of the economic cycle.

This makes the business defensive and reliable. Sonic's revenue is built on millions of routine tests, which provide a steady base of demand that grows over time. An ageing population, the rising prevalence of chronic disease, and advances in testing all support Long-term Growth in test volumes. The 5% organic growth in FY2026 reflects this durable, demographic-driven demand — the bedrock on which the whole business rests.

The breadth of the demand also insulates Sonic from any single change in medical practice. No one test dominates its revenue; income is spread across thousands of different assays ordered by many doctors for a vast range of conditions. If demand for one test fades, others grow to replace it, and the overall trend of medicine is toward more testing, as earlier diagnosis, screening and personalised treatment all rely on laboratory results. That diversity, layered on top of the non-discretionary nature of testing, is what makes the base so stable.

The power of scale

Pathology is a business where scale matters enormously. Running laboratories involves significant fixed costs — equipment, facilities, skilled staff — so processing more tests through the same infrastructure lowers the cost per test and improves margins. A large operator like Sonic can invest in efficient, high-throughput laboratories and spread those costs over a huge volume of tests, giving it a cost advantage over smaller rivals.

The risks

Sonic faces several risks. Pathology is heavily dependent on government and insurer funding, and changes to reimbursement rates — such as regulatory changes flagged in Switzerland — can reduce revenue and margins. Cost inflation, particularly in labour, can pressure margins if not offset by volume and efficiency. Organic growth can be affected by the level of testing, which normalised after unusually high pandemic-related demand in earlier years.

Acquisitions carry integration and valuation risk, and Sonic must keep finding and absorbing them to sustain its acquisition-led growth. Operating globally, it is exposed to currency movements and to different regulatory and healthcare systems. Competition exists in each market. The business also carries the operational and quality risks inherent in laboratory testing, where accuracy is paramount. Broad healthcare-policy changes could affect demand or funding across its markets.